GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (OTCPK:CRRTF) » Definitions » Price-to-Owner-Earnings

Crescita Therapeutics (Crescita Therapeutics) Price-to-Owner-Earnings : 6.40 (As of Apr. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Price-to-Owner-Earnings?

As of today (2024-04-27), Crescita Therapeutics's share price is $0.32. Crescita Therapeutics's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.05. It's Price-to-Owner-Earnings for today is 6.40.


The historical rank and industry rank for Crescita Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

CRRTF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.92   Med: 5.1   Max: 134
Current: 6.3

During the past 10 years, the highest Price-to-Owner-Earnings of Crescita Therapeutics was 134.00. The lowest was 1.92. And the median was 5.10.


CRRTF's Price-to-Owner-Earnings is ranked better than
92.64% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.64 vs CRRTF: 6.30

As of today (2024-04-27), Crescita Therapeutics's share price is $0.32. Crescita Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.07. Therefore, Crescita Therapeutics's PE Ratio for today is At Loss.

As of today (2024-04-27), Crescita Therapeutics's share price is $0.32. Crescita Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.07. Therefore, Crescita Therapeutics's PE Ratio without NRI for today is At Loss.

During the past 10 years, Crescita Therapeutics's highest PE Ratio without NRI was 177.50. The lowest was 0.00. And the median was 9.41.


Crescita Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Crescita Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics Price-to-Owner-Earnings Chart

Crescita Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.26 4.19 - - 7.00

Crescita Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 48.95 - 7.00

Competitive Comparison of Crescita Therapeutics's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Price-to-Owner-Earnings falls into.



Crescita Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Crescita Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.32/0.05
=6.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Crescita Therapeutics  (OTCPK:CRRTF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Crescita Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescita Therapeutics (Crescita Therapeutics) Business Description

Traded in Other Exchanges
Address
2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue in the form of product sales and out-licensing revenue.